Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway

Virology

Volumn 240, Issue 1, 1998, Pages 147-157

  Peng, Shiwen ^a   Frazer, Ian H ^a   Fernando, Germain J ^a   Zhou, Jian ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; EPITOPE; GLYCOPROTEIN GP 160; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HEMAGGLUTINATION; IMMUNIZATION; MOUSE; NONHUMAN; PAPILLOMA VIRUS; PRIORITY JOURNAL; TUMOR CELL; VIRUS NEUTRALIZATION; VIRUS PARTICLE; WART VIRUS;

ANIMALIA; BOVINAE; BOVINE PAPILLOMAVIRUS; BOVINE PAPILLOMAVIRUS TYPE 1; DNA VIRUSES; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS;

EID: 0032484471     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1997.8912     Document Type: Article

References (60)

1. Adams S. E., Dawson K. M., Gull K., Kingsman S. M., Kingsman A. J. The expression of hybrid HIV:Ty virus-like particles in yeast. Nature. 329:1987;68-70.
2. Alloub M. I., Barr B. B., McLaren K. M., Smith I. W., Bunney M. H., Smart G. E. Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts. Br. Med. J. 298:1989;153-156.
3. Bevan M. J. Antigen recognition. Class discrimination in the world of immunology [news]. Nature. 325:1987;192-194.
4. Braciale T. J., Morrison L. A., Sweetser M. T., Sambrook J., Gething M. J., Braciale V. L. Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes. Immunol. Rev. 98:1987;95-114.
5. Chen L. P., Thomas E. K., Hu S. L., Hellstrom I., Hellstrom K. E. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc. Natl. Acad. Sci. USA. 88:1991;110-114.
6. Christensen N. D., Reed C. A., Cladel N. M., Han R., Kreider J. W. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J. Virol. 70:1996;960-965.
7. Clarke B. E., Newton S. E., Carroll A. R., Francis M. J., Appleyard G., Syred A. D., Highfield P. E., Rowlands D. J., Brown F. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature. 330:1987;381-384.
8. Clerici M., Lucey D. R., Zajac R. A., Boswell R. N., Gebel H. M., Takahashi H., Berzofsky J. A., Shearer G. M. Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. J. Immunol. 146:1991;2214-2219.
9. Coleman N., Birley H. D., Renton A. M., Hanna N. F., Ryait B. K., Byrne M., Taylor Robinson D., Stanley M. A. Immunological events in regressing genital warts. Am. J. Clin. Pathol. 102:1994;768-774.
10. Crook T., Morgenstern J. P., Crawford L., Banks L. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J. 8:1989;513-519.
11. Dalsgaard K. Saponin adjuvants. 3. Isolation of a substance from Quillaja saponaria Molina with adjuvant activity in food-and-mouth disease vaccines. Arch. Gesamte. Virusforsch. 44:1974;243-254.
12. De Bruijn M. L., Jackson M. R., Peterson P. A. Phagocyte-induced antigen-specific activation of unprimed CD8+ T cells in vitro. Eur. J. Immunol. 25:1995;1274-1285.
13. Evander M., Frazer I. H., Payne E., Qi Y. M., Hengst K., McMillan N. A. Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. J. Virol. 71:1997;2449-2456.
14. Evans D. J., McKeating J., Meredith J. M., Burke K. L., Katrak K., John A., Ferguson M., Minor P. D., Weiss R. A., Almond J. W. An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature. 339:1989;385-8,340.
15. Falo L. D. Jr., Kovacsovics Bankowski M., Thompson K., Rock K. L. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat. Med. 1:1995;649-653.
16. Feltkamp M. C., Smits H. L., Vierboom M. P., Minnaar R. P., de Jongh B. M., Drijfhout J. W., ter Schegget J., Melief C. J., Kast W. M. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23:1993;2242-2249.
17. Fernando, G. J. Stewart, T. Tindle, R. W. Frazer, I. H. 1997, Induction of tumour antigen specific CTL mediated tumour protection is not altered by prior induction of a TH2 type response specific for the same tumour antigen.
18. Frazer I. H., Medley G., Crapper R. M., Brown T. C., Mackay I. R. Association between anorectal dysplasia, human papillomavirus, and human immunodeficiency virus infection in homosexual men. Lancet. 2:1986;657-660.
19. Germain R. N., Margulies D. H. The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol. 11:1993;403-450.
20. Goldberg A. L., Rock K. L. Proteolysis, proteasomes and antigen presentation. Nature. 357:1992;375-379.
21. Griffiths J. C., Harris S. J., Layton G. T., Berrie E. L., French T. J., Burns N. R., Adams S. E., Kingsman A. J. Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: Induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion. J. Virol. 67:1993;3191-3198.
22. Harding C. V., Pfeifer J. D. Antigen expressed by Salmonella typhimurium is processed for class I major histocompatibility complex presentation by macrophages but not infected epithelial cells. Immunology. 83:1994;670-674.
23. Jenkins O., Cason J., Burke K. L., Lunney D., Gillen A., Patel D., McCance D. J., Almond J. W. An antigen chimera of poliovirus induces antibodies against human papillomavirus type 16. J. Virol. 64:1990;1201-1206.
24. Ke Y., Li Y., Kapp J. A. Ovalbumin injected with complete Freund's adjuvant stimulates cytolytic responses. Eur. J. Immunol. 25:1995;549-553.
25. Kirnbauer R., Booy F., Cheng N., Lowy D. R., Schiller J. T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA. 89:1992;12180-12184.
26. Kovacsovics Bankowski M., Clark K., Benacerraf B., Rock K. L. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl. Acad. Sci. USA. 90:1993;4942-4946.
27. Kovacsovics Bankowski M., Rock K. L. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science. 267:1995;243-246.
28. Kulski, J. K. Sadleir, J. W. Kelsall, S. R. Cicchini, M. S. Shellam, G. Peng, S. W. Qi, Y. M. Zhou, J. Frazer, I. H. Type-specific and genotype cross reactive B epitopes of the L1 protein of HPV16 defined by a panel of monoclonal antibodies.
29. Lambert P. F., Pan H., Pitot H. C., Liem A., Jackson M., Griep A. E. Epidermal cancer associated with expression of human papillomavirus type 16 E6 and E7 oncogenes in the skin of transgenic mice. Proc. Natl. Acad. Sci. USA. 90:1993;5583-5587.
30. Lanzavecchia A. Mechanisms of antigen uptake for presentation. Curr. Opin. Immunol. 8:1996;348-354.
31. Layton G. T., Harris S. J., Gearing A. J., Hill Perkins M., Cole J. S., Griffiths J. C., Burns N. R., Kingsman A. J., Adams S. E. Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like particles. J. Immunol. 151:1993;1097-1107.
32. Liu W. J., Gissmann L., Sun X. Y., Kanjanahaluethai A., Muller M., Doorbar J., Zhou J. Sequence close to the N-terminus of L2 protein is displayed on the surface of bovine papillomavirus type 1 virions. Virology. 227:1997;474-483.
33. Londono L. P., Chatfield S., Tindle R. W., Herd K., Gao X. M., Frazer I., Dougan G. Immunisation of mice using Salmonella typhimurium expressing human papillomavirus type 16 E7 epitopes inserted into hepatitis B virus core antigen. Vaccine. 14:1996;545-552.
34. Meneguzzi G., Cerni C., Kieny M. P., Lathe R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology. 181:1991;62-69.
35. Michel M. L., Mancini M., Schlienger K., Tiollais P. Recombinant hepatitis B surface antigen as a carrier of human immunodeficiency virus epitopes. Res. Virol. 144:1993;263-267.
36. Moore M. W., Carbone F. R., Bevan M. J. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell. 54:1988;777-785.
37. Muller M., Zhou J., Reed T. D., Rittmuller C., Burger A., Gabelsberger J., Raspenning J., Gissmann L. Chimeric papillomavirus-like particles. Virology. 234:1997;93-111.
38. Norbury C. C., Hewlett L. J., Prescott A. R., Shastri N., Watts C. Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages. Immunity. 3:1995;783-791.
39. Paintsil J., Muller M., Picken M., Gissmann L., Zhou J. Carboxyl terminus of bovine papillomavirus type-1 L1 protein is not required for capsid formation. Virology. 223:1996;238-244.
40. Pfeifer J. D., Wick M. J., Roberts R. L., Findlay K., Normark S. J., Harding C. V. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature. 361:1993;359-362.
41. Qi Y. M., Peng S. W., Hengst K., Evander M., Park D. S., Zhou J., Frazer I. H. Epithelial cells display separate receptors for papillomavirus VLPs and for soluble L1 capsid protein. Virology. 216:1996;35-45.
42. Ressing M. E., Sette A., Brandt R. M., Ruppert J., Wentworth P. A., Hartman M., Oseroff C., Grey H. M., Melief C. J., Kast W. M. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol. 154:1995;5934-5943.
43. Rock K. L. A new foreign policy: MHC class I molecules monitor the outside world. Immunol. Today. 17:1996;131-137.
44. Roden R. B., Weissinger E. M., Henderson D. W., Booy F., Kirnbauer R., Mushinski J. F., Lowy D. R., Schiller J. T. Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J. Virol. 68:1994;7570-7574.
45. Roden R. B., Hubbert N. L., Kirnbauer R., Breitburd F., Lowy D. R., Schiller J. T. Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor. J. Virol. 69:1995;5147-5151.
46. Schlienger K., Mancini M., Riviere Y., Dormont D., Tiollais P., Michel M. L. Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates. J. Virol. 66:1992;2570-2576.
47. Schulz M., Zinkernagel R. M., Hengartner H. Peptide-induced antiviral protection by cytotoxic T cells. Proc. Natl. Acad. Sci. USA. 88:1991;991-993.
48. Sedlik C., Saron M. F., Sarraseca J., Casal I., Leclerc C. Recombinant parvovirus-like particles as an antigen carrier: A novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc. Natl. Acad. Sci. USA. 94:1997;7503-7508.
49. Sugita M., Brenner M. B. Association of the invariant chain with major histocompatibility complex class I molecules directs trafficking to endocytic compartments. J. Biol. Chem. 270:1995;1443-1448.
50. Takahashi H., Cohen J., Hosmalin A., Cease K. B., Houghten R., Cornette J. L., DeLisi C., Moss B., Germain R. N., Berzofsky J. A. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA. 85:1988;3105-3109.
51. Tindle R. W., Herd K., Londono P., Fernando G. J., Chatfield S. N., Malcolm K., Dougan G. Chimeric hepatitis B core antigen particles containing B- and Th-epitopes of human papillomavirus type 16 E7 protein induce specific antibody and T-helper responses in immunised mice. Virology. 200:1994;547-557.
52. Tindle R. W., Croft S., Herd K., Malcolm K., Geczy A. F., Stewart T., Fernando G. J. A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants. Clin. Exp. Immunol. 101:1995;265-271.
53. Tindle R. W., Frazer I. H. Immune response to human papillomaviruses and the prospects for human papillomavirus-specific immunisation. Curr. Top. Microbiol. Immunol. 186:1994;217-253.
54. Townsend A., Trowsdale J. The transporters associated with antigen presentation. Semin. Cell Biol. 4:1993;53-61.
55. Winter N., Lagranderie M., Gangloff S., Leclerc C., Gheorghiu M., Gicquel B. Recombinant BCG strains expressing the SIVmac251nef gene induce proliferative and CTL responses against nef synthetic peptides in mice. Vaccine. 13:1995;471-478.
56. Zhou F., Rouse B. T., Huang L. Induction of cytotoxic T lymphocytes in vivo with protein antigen entrapped in membranous vehicles. J. Immunol. 149:1992;1599-1604.
57. Zhou J., Sun X. Y., Stenzel D. J., Frazer I. H. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 185:1991;251-257.
58. Zhou J., Gissmann L., Zentgraf H., Muller H., Picken M., Muller M. Early phase in the infection of cultured cells with papillomavirus virions. Virology. 214:1995;167-176.
59. Zhu X., Tommasino M., Vousden K., Sadovnikava E., Rappuoli R., Crawford L., Kast M., Melief C. J., Beverley P. C., Stauss H. J. Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein ofhuman papilloma virus 16 in H-2d mice. Scand. J. Immunol. 42:1995;557-563.
60. zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology. 184:1991;9-13.